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Human kidney homotransplantation was first attempted on a large 
scale in 1962 and 1963. Even its most enthusiastic proponents could 
not then predict that this procedure would within five years become 
the preferred and the most effective way of treating patients with 
renal failure. Almost all previous trials had ended in the early death 
of the recipient [12] with the few notable exceptions recorded by 
MERRILL [48], HAMBURGER [17, 19], Kuss [40], and SHACKMAN [67]. 
There are today only two patients still alive who were treated before 
1962, one from Boston and the other from Paris; both received 
kidneys from fraternal twins. Immunosuppression was with total body 
radiation, a technique of host conditioning which has been replaced 
in most centers by drug therapy. In contrast, successes in the suc-
ceeding years have been reported by many authors [6, 18,27, 35, 36, 
45, 55,69, 101]. 
In this report, several issues will be reviewed on the basis of our 
earlier experience with human renal transplantation. The questions 
to be examined in distant retrospect concern the homograft rejection 
seen after clinical renal transplantation and the measures necessary to 
control and reverse this process; the life expectancy of patients 
brought through early rejection episodes; the effect of prospective 
histocompatibility matching upon survival; and the early and delayed 
influence of thymectomy upon kidney transplant function. More 
recent developments will also be mentioned including the use of 
heterologous antilymphocyte globulin (ALG) in man, the role of the 
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Shwartzman reaction in "hyperacute rejection", the development of 
neoplasms after transplantation, attempts to alter graft antigenicity 
with ribonucleic acid (RNA) infusion, and the extension of trans-
plantation techniques to human liver replacement. 
Renal Homotransplantation 
The Reversal of Rejection and Subsequent Adaptation or Tolerance 
One of the most important contributions of clinicians was the demon-
stration that rejection is a highly reversible process. This concept had 
not emerged from the skin graft experiments upon which the founda-
tions of transplantation biology were largely based, nor was it evident 
in the first trials of either canine or human renal homotransplantation. 
It is probable in retrospect that the Boston and Paris fraternal 
twins mentioned earlier both passed through rejection crises. The 
events in HAMBURGER'S case [17] were the most clear. For almost 
three weeks after operation, the transplanted kidney functioned per-
fectly. Fever, azotemia, and proteinuria then developed, but within 
a ten day period these findings receded without the institution of any 
specific therapy. HAMBURGER ascribed the changes to a spontaneously 
reversible immunologic crisis. 
Evaluation of the course in MERRILL'S case [48] was made difficult 
by complicating circumstances. Immediate good renal function was 
also obtained. Within a few weeks, fever and a rise in BUN were seen, 
but at the same time the patient's own kidneys had cortical and 
perinephric abscesses. After nephrectomies and drainage, the deterio-
ration was reversed and MERRILL concluded that "the oliguria and 
nitrogen retention ... were clearly associated with an episode of in-
fection". Eight months later, a homograft biopsy revealed mono-
nuclear cell invasion and other morphologic evidence of chronic 
rejection. Although function was stable and essentially normal, ad-
ditional total body irradiation was given as well as a course of adrenal 
corticosteroids. Their opinion at the time these observations were 
reported was that a rejection had been thereby" aborted"; it is now 
well known as will be discussed later that kidney grafts, found with 
late biopsy to have such histologic changes, may function for years 
without intensification of therapy and without clinically evident re-
jection [61, 78]. In commenting on the significance and the earlier 
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timing of events in HAMBURGER'S case, MERRILL said [48] "it seems 
highly unlikely ... that in a partially tolerant patient, rejection would 
begin at the time at which it might be expected for the non-tolerant 
person, only to abort spontaneously". 
The first suggestion that rejection was a highly controllable and 
reversible phenomenon came from our institution [82]. That report 
began as follows: 
"Because of the high failure rate after renal homotransplantation, there has been an 
air of pessimism concerning the possibility of long term function of the grafted kidney. 
The immunologic processes subserving rejection are generally thought to be so powerful 
and persevering that consistent success cannot be expected with the use of any of the 
currently available methods of antirejection therapy. 
Recent personal experience in caring for patients with renal homografts has resulted 
in alterations in many of our preconceived notions concerning the management of such 
patients. It has led to the beliefs that the rejection process can almost never be entirely 
prevented, but that its effects can be reversed with a high degree of regularity and com-
pleteness. Furthermore, the subsequent behavior of patients who have been brought 
through a successfully treated rejection crisis suggests the early development of some 
degree of host-graft adaptation, since the phenomenon of vigorous secondary rejection 
has been encountered only once." 
In that series there were ten patients treated in late 1962 and early 
1963. In seven, clear cut rejection of variable intensity occurred from 
4 to 34 days after operation (fig. 1), in one case actually leading to 
anuria. In each instance, the process was reversed by the addition of 
massive doses of prednisone to the pre-existing therapy with azathio-
prine (fig. 1). Three of these 7 patients are still alive five or more 
years later and are now amongst the longest living recipients of non-
twin homo grafts in the world. After the remarkable effectiveness of 
steroid therapy in this situation had been established from our own 
experience, but before our findings were published, it was learned 
that the same kind of observation had been made by GOODWIN and 
his associates [11] in a young woman who ultimately died of sepsis 
144 days after receipt of a maternal homograft. It was realized almost 
from the beginning that a reduction in homograft blood flow was an 
integral component of rejection crises and that the pharmacologically 
induced reversal was accompanied by relief of the organ ischemia 
[69, 77]; both conclusions have been corroborated in animal experi-
ments [38, 39, 64, 65]. 
The reversibility of rejection in these patients was only one of the 
features which established the clinical feasibility of organ transplanta-
tion. The quantities of adrenal corticosteroids necessary to achieve 
reversal were often extremely large, too great for reasons of toxicity 
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to be compatible with long survival of the recipient if continued 
indefinitely. Fortunately, another event of equal practical importance 
transpired coincidentally with the reversal of rejection or shortly 
afterwards. With the passage of time, the need for intensive therapy 
usually diminished both in patients who did and those who did not 
pass through a clinically evident rejection. Thus, the patient whose 
course is depicted in figure 1 had returned within five months after 
transplantation to treatment only with azathioprine, a drug which at 
the outset did not prevent the onset of a moderately severe rejection. 
An ultimate similar reduction in drug requirement is today seen in 
almost all new cases and it is probable that some patients could 
URINE 
6,000 
5,000 
OUTPUT 4,000 
Icc/dayl 
CCr 100 
Icc/minI 
SO 
BUN 
Img%1 
IMURAN 
Img/dayl 
PREDNISONE 100 Img/dayl 
200 
50,000 
Transplant 
and LN 
Time in days 
PATIENT J.R. 
IAGE 23 0"1 
Transplant 
and LN 
Fig. 1. Classical rejection crisis in patient (LD 6) treated with drugs alone. Deterioration 
of renal function began 19 days after transplantation. All stigmata of rejection were 
present except for acute hypertension and weight gain, which were successfully prevented 
by medical treatment. Acti-C---Actinomycin C; LN---Left nephrectomy at time of 
transplantation; RN ---Right nephrectomy. Imuran is synonymous with azathioprine. 
(By permission of Surg. Gynec. Obstet. 117: 385, 1963.) 
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eventually have all therapy stopped. In our laboratory, we have dogs 
living for four to five years which were given treatment with immuno-
suppressants only for the first four months after receipt of life sustain-
ing liver or renal homografts from non-related mongrel donors. 
The foregoing phenomenon is so poorly understood that it is 
still reasonable to refer to it by the originally used term [82] of 
"a change in the graft-host relationship". Earlier animal experiments 
of WOODRUFF and WOODRUFF suggested that a metamorphosis occurs 
in transplants after long residence in a host [103], but, as MCGAVIC 
and MURRAY of Boston showed [47, 54] by some other mechanism 
than an alteration in intrinsic graft antigenicity. Both MERRILL [48] 
and MCGAVIC [47] concluded that there was a host change (partial 
tolerance) but on the basis of observations [47, 48, 54] that actually 
tended to support WOODRUFF'S point of view. 
Whatever the explanation, there is no longer reason to doubt that 
a homograft becomes more or less privileged if it can be kept alive 
through the initial onslaught of rejection. This fact is detectable in 
the shape of life survival curves after renal homotransplantation in 
that the preponderant mortality is in the first few postoperative weeks 
or months when stringent immunosuppression is required. It has 
strongly influenced the way in which new therapeutic agents such as 
heterologous antilymphocyte globulin (ALG) have been used clinical-
ly, and it has been a prime stimulus for the extension of transplantation 
techniques to organs other than the kidney. 
Chronically Tolerated Renal Homografts 
Up-to-date reports about patients provided with renal homografts 
several years ago are still of vital current interest since this is the only 
data with which to obtain an idea of the long term prognosis of more 
recently treated recipients. Consequently, the cases compiled in Denver 
between the autumn of 1962 and March 1964 are particularly useful 
since it is the first series in which a large number of patients were 
successfully brought through the first few postoperative months. 
There were 64 recipients who received their kidneys from healthy 
volunteers; 30 (47 %) of that original group are still alive. 
The most encouraging results were where intrafamilial transplanta-
tion was the original procedure. There were 46 recipients of con-
sanguineous kidneys. Of these, 15 died within the first year, but only 
1, 1, and 1 were lost during the second, third, and fourth postoperative 
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Fig. 2. Life survival curves of 64 patients treated in Denver with renal homotrans-
plantation between November 1962 and March 1964. Preoperative histocompatibility 
testing was not done. The vertical arrows indicate the time of minimum followup. 
years (fig. 2). The present survival after 4 to 51/ 3 years is 28 of 46 
(60.9 %). None of the 28 patients have received late retransplantation 
and none have been returned to dialysis programs. The function of 
these chronically tolerated homo grafts has been shown by OGDEN [57] 
to be generally almost as good as the contralateral kidneys left in their 
donors. 
With recipients of non-related homografts, the picture was by no 
means as good. There was a heavier early mortality inasmuch as 
12 of the 18 patients entered into the series had died by the end of 
the first year (fig. 2). Furthermore, a steady attrition continued there-
after. Two more patients died in the second postoperative year, as 
well as another two who reached 33 and 51 months respectively. 
There are now only two of the original 18 recipients alive, one by 
virtue of a second homotransplantation 2 Y2 years after the first. The 
other patient has had continuous excellent function from his non-
related homograft for more than four years. 
The foregoing observations in a large series of transplantations 
have made it clear that survival for several years can often be obtained, 
particularly if related donors can be found. However, it can hardly 
be expected that most of these homo grafts will function for a normal 
lifetime since the presence in them of more or less serious structural 
abnormalities is the rule rather than the exception. This conclusion 
was reached by Dr. K.A. PORTER of St. Mary's Hospital and Medical 
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School, London, on the basis of examination of 2-year renal biopsies 
obtained from all Denver patients who survived this long [60, 61]. 
An occasional homograft was completely normal. However, in the 
others there were pathologic changes which were not always reflected 
in impairment of renal function. There were vascular lesions; fibrous 
thickening of the intima of interlobular arteries often with rupture 
or duplication of the internal elastic lamina, deposition of a hyaline-
like substance in the subintimal layer of afferent arterioles and deposi-
tion of the same PAS-positive hyaline material in the glomerular 
capillaries. The last finding has been shown by HARLAN et al. [20] to 
often be associated with a nephrotic syndrome. 
The homo grafts with vascular lesions often had other secondary 
morphologic changes including fibrosis of the glomerular tufts, spotty 
periglomerular fibrosis, interstitial fibrosis, or tubular atrophy. The 
majority of the homografts also contained focal accumulations of 
mononuclear cells. Ten to 40 % of these cells consisted of the pyronin-
ophilic variety which are found in acutely rejecting homografts. In 
the chronically functioning homo grafts, the presence of such cells 
was not incompatible with good or even normal long term function. 
Further studies by PORTER and his associates with immunofluor-
escence techniques and with ferritin-conjugated antisera have shed 
additional light on some of the foregoing changes [60]. The deposits 
in the subendothelial layers of small vessels and glomerular capillaries 
were shown to consist at least in part of host antibodies, particularly 
in the IgM class but also often including complement, IgG, and 
fibrinogen. These were considered to represent the reaction of circu-
lating host antibodies with antigens in the capillary basement mem-
branes of the transplanted kidney. 
In three exceptional grafts, the deposits were nodular and were 
along the subepithelial side of the glomerular capillary basement 
membranes. The authors suggested that these were caused by the 
transmission of active glomerulonephritis from the recipient to the 
homograft [60]. Morphologic evidence that this sequence of events 
was possible had previously been published by PORTER [62], O'BRIEN 
and HUME [56], and PETERSEN et al. [59]. More recently, LERNER et al. 
[43] have conclusively shown that anti-glomerular basement mem-
brane (anti-GBM) antibodies present in the serum of a patient with 
active glomerulonephritis fixed to and adversely effected a subsequent 
transplanted homograft. Presumably, this complication could be 
avoided if patients with acute or subacute glomerulonephritis were 
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subjected to preliminary nephrectomy and transplantation were then 
deferred until recipient serum levels of anti-GBM antibody disap-
peared. 
The fact that many, or even most, renal homografts may gradually 
fail is not a serious argument against further clinical transplantation. 
The degree of social and vocational rehabilitation in the interval of 
satisfactory kidney function is usually relatively complete. Moreover, 
it is now known chiefly as the result of HUME'S work [27], that 
retransplantation for the indication of a failing first homograft can 
be done with a reasonable expectation of success. This expedient was 
considered too late in some of the patients in our early series who died 
long after operation with diminishing renal function. 
Histocompatibility Typing 
During the time when the first Denver series was accumulated, there 
were no practical methods of predicting the vigor or tenacity of the 
anticipated rejection process. It was quickly recognized that red blood 
cell group incompatibilities between donors and recipients could lead 
to immediate loss of the transplanted kidneys, from which experience 
the now widely accepted rules were formulated [69, 75] concerning 
tissue transfer between people of different ABO types (table I). Since 
other preoperative analyses of donor-recipient compatibility were not 
available, the transplantation itself became a test system in which, 
presumably, the recipients of biologically unfavorable kidneys were 
ruthlessly weeded out in the early mortality. It was decided to retrieve 
the information derived from this unacceptable situation and use it 
to try to improve donor selection for future cases. The effort involved 
a collaboration with Dr. P. TERASAKI of Los Angeles, and Dr. K.A. 
PORTER of London, England. In the meanwhile, a six month mora-
torium on new cases was declared. 
For some years, TERASAKI, DAUSSET, PAYNE, VAN ROOD, CEP-
PELLINI, AMOS, and others [23] had been working on the characteriza-
tion with a variety of serologic techniques of the antigens contained 
in leukocytes. These workers were convinced that most of the antigens 
contained in renal and other tissue were also to be found in the readily 
accessible peripheral lymphocytes. By studying the lymphocytes of 
prospective donors and recipients, it was hoped that an idea could be 
obtained of their general tissue compatibility. Unfortunately, there 
was at that time no proof that the antigen systems under investigation 
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had any direct or indirect relationship to histocompatibility and it was 
to establish this point that the Denver patients were employed. 
First, TERASAKI analyzed the antigenic constitution of a number 
of surviving recipients and their donors using his lymphocyte cyto-
toxicity test. The quality of the matches was graded and compared 
with clinical rankings accorded by those caring for the patients. The 
correlation was imperfect. It was evident that many patients had 
retained good homograft function for long periods in spite of what 
appeared to be poor matches with their donors. Nevertheless, most 
of the really superior clinical results were in patients who had received 
exceptionally well matched kidneys [78,91]. Later, a far more striking 
correlation was found between the Terasaki results and the degree of 
histologic injury noted by PORTER in the two year biopsies mentioned 
in the preceding section [61]. 
Although much of the above-cited support for the validity of 
antigen typing was not yet available in 1964, there was even then 
enough favorable evidence to warrant a prospective clinical evaluation. 
When transplantation was resumed in October of that year, an effort 
was made by TERASAKI in every case to find the best possible donor 
amongst the volunteers available for each patient. 
The selectivity was severely limited in most cases of intrafamilial 
transplantation. In most instances, only one or two blood relative 
were willing to donate or were acceptable on general medical or 
psychiatric grounds. Consequently, the matching was not improved 
to a statistically significant degree over that which could have been 
achieved with random intrafamilial pairing [88]. It was not, therefore, 
surprising to find that the ultimate survival in these related cases 
(fig. 3) was almost identical to that defined in the earlier Series 1. Of 
25 recipients, 16 (64%) were still alive at one year. Two more sub-
sequently died after 26 and 30 months leaving a residual group of 14 
(56 %) with a follow-up of 23 months to 3lh years. 
In the 17 non-related homotransplantations, the situation was dif-
ferent in that donors were picked from a pool which included as many 
as 80 volunteers. Perfect matches could not be found, but the quality 
of the pairing was improved over that which could have been ex-
pected by chance [88]. The recipients fared better than previously 
observed in Series 1. Nine (52.9 %) of the 17 recipients were still alive 
at the end of the first year (fig. 3). Three more patients were lost at 
18,27, and 35 months respectively but in two of these there was life 
sustaining renal function until death. Six of the 17 patients (35.3 %) 
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Fig. J. Survival of 42 patients treated with renal homotransplantation between October 
1964 and April 1966. An attempt was made by TERASAKI to select the most compatible 
donor amongst available volunteers. See text for discussion of results. 
are still living with good to excellent function of their original homo-
grafts from 28 to 40 months after transplantation. The mean creatinine 
clearance in the remaining group is 83.4 ± 26.2 (SD) ml/min. 
In both the related and non-related cases, observations were made 
which were similar to those made retrospectively in Series 1. Several 
recipients of poorly matched kidneys fared surprisingly well. A few 
patients with good matches experienced vigorous and prolonged re-
jection. However, the preponderance of the best results were in cases 
in which a close antigen match had been present. 
The failure to improve survival at all in the related transplantations 
or to increase it more in the non-related cases was a keen disappoint-
ment since evidence from many investigators now suggested more 
strongly than ever that the tissue typing being used provided a 
measure of histocompatibility antigens [7, 41, 58, 63, 83, 90, 93, 98]. 
It seemed that safer methods of immunosuppression would be re-
quired before histocompatibility typing could receive a fair trial. 
It had been recognized for several years that many and possibly 
even most of the deaths after clinical homotransplantation were due 
to drug toxicity. At the beginning, bone marrow depression from 
overdoses of azathioprine had been common, but with increased 
experience this complication was now rarely seen. Avoidance of the 
hazards of the steroid therapy which is usually combined with aza-
thioprine was not so simple. In many cases, it had been found that 
continued function of a homograft was dependent upon continuation 
Be 
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for long periods of unacceptably large quantities of prednisone. The 
complications which followed were exceedingly troublesome at best, 
and lethal at worst. These included cosmetic deformity, bone de-
mineralization often with spontaneous fractures, muscle wasting, 
arrest of growth in infants, fatty infiltration of the liver, pancreatitis, 
and gastrointestinal ulceration and hemorrhage to name just a few. 
Most serious, however, was the consequent susceptibility to micro-
organisms of all types. 
If the resultant infections were due to common pathogenic bacteria 
they could be treated effectively with properly chosen antibiotics. Very 
often, however, these were caused by fungi, protozoa, or viruses for 
which specific therapy was not available. The tragic consequences 
are illustrated in figure 4. This patient, who received a homograft 
from his brother, had an early rejection crisis followed by excellent 
renal function for the next nine months. After reduction of his 
prednisone to 10 mgjday, he had a delayed rejection which was 
controlled by increasing the prednisone dose to a level from which 
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Fig. 4. Course of a 37-year-old man (LD 47) who received a kidney from his younger 
brother. Both were A + blood type. Note the severe late rejection after nine months and 
the subsequent slow deterioration of renal function. The late thymectomy did not induce 
either lymphopenia or make the subsequent management easier; the post-thymectomy 
changes in lymphocyte counts were related to adjustments in steroid dosage. (By per-
mission of Ann. N. Y. Acad. Sci. 129: 605, 1966). 
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subsequent withdrawals were not possible without further deteriora-
tion of kidney function. He died 15 months later but not primarily 
from renal failure. He had fatty infiltration of the liver, a duodenal 
ulcer, and pancreatitis. There were cytomegalic inclusion viruses in 
the lungs and liver, and diffuse pneumonitis due to Pneumocystis 
carinii and Aspergillus fumigatum. 
Improvements in Immunosuppression 
For the aforementioned reasons, intensive efforts have been made in 
a number oflaboratories to develop new and safer immunosuppressive 
agents. The most encouraging results have been with heterologous 
antilymphocyte serum (ALS) or its globulin derivative (ALG). These 
biologic agents were first evaluated in animals for their ability to 
prevent rejection by W AKSMAN et al. [95] and WOODRUFF and ANDER-
SON [102]. Notable contributions have since been made by MONACO 
and RUSSELL and their collaborators [13,51,52], LEVEY and MEDAWAR 
[44], and many others [100]. 
In our laboratory, the horse has been used as the source of immune 
serum [28, 76]. After immunization with the lymphoid tissue of the 
species to be eventually treated, the horses are bled and the serum is 
separated. Undesirable anti-red cell and anti-plasma protein antibodies 
are absorbed with donor species red cells and plasma or serum. The 
antilymphocyte antibodies which are in the IgG fraction of the horse 
serum can then be removed with several techniques. Initially, we 
employed ammonium sulphate precipitation for crude globulin extrac-
tion (fig. 5) but more recently pure IgG has been removed in bulk 
quantities (fig. 6) by batch mixing with DEAE cellulose [33]. The 
ALG can then be given by intramuscular injection. 
The guidelines for the clinical use of heterologous ALG were 
provided by extensive investigations in dogs. The ability of the anti-
dog-lymphocyte globulin to mitigate homograft rejection was easily 
and unequivocally demonstrated [74, 76]. Nevertheless, the degree 
of protection was incomplete. In about a fourth of the animals rejec-
tion proceeded as might have been expected in untreated animals. Its 
onset was delayed or occasionally prevented altogether in the rest of 
the animals. However, survival of as long as 4, 8, or 12 months was 
observed in the minority of recipients of kidneys or livers. This 
spectrum of results was similar to that which can be obtained in dogs 
with other potent immunosuppressive agents such as azathioprine. 
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Fig. 5. Electrophoresis and immunoelectrophoresis of absorbed antihumanlymphoid 
serum and the protein obtained from it by two precipitations with 0.4 saturated am-
monium sulphate, two dialyses, and lyophilization. The final product, which was used 
clinically, consisted mostly of gamma G globulin but it usually contained small quantities 
of alpha and beta globulins. (By permission of Surg. Gynec. Obstet. 124: 1, 1967.) 
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Fig. 6. Electrophoretic and immunoelectrophoretic patterns of unabsorbed antihuman 
ALS, the raw globulin obtained with a single ammonium sulphate precipitation of ab-
sorbed ALS, and the final product (pure gamma G globulin) after subsequent DEAE-
cellulose batch extraction. 
Other factors concerned with the toxicity of ALG influenced the 
therapeutic program finally adopted [28, 72, 76, 81]. After long term 
administration, the animals usually developed antibodies against the 
injected horse protein. Many of these dogs ultimately had microscopic 
renal lesions which consisted of deposits of horse protein, together 
with host gamma globulin and complement; the findings were 
characteristic of serum sickness nephritis [28]. 
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For all these reasons it was decided to use ALG only as an adjuvant 
to the standard immunosuppressive agents azathioprine and predni-
sone. The regimen ordinarily followed is shown in figure 7. ALG 
was started a few days in advance of transplantation, continued daily 
for the first 10 to 14 postoperative days, then every other day for 
two weeks, twice a week for two months and once a week for a final 
month. The four month duration of the ALG course was selected 
since the greatest need for improvements in therapy was in this 
postoperative period of high risk. It was anticipated that an at least 
partial evolution of the state of "host-graft non-reactivity" discussed 
earlier would have occurred by the end of this time and that the 
need for maintenance treatment would be correspondingly reduced. 
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Fig. 7. The course of a patient who received antilymphocyte globulin (ALG) before 
and for the first four months after renal homotransplantation. The donor was an older 
brother. The Terasaki match was a good one. There was no early rejection. Prednisone 
therapy was started 40 days postoperatively because of the high rises in the serologic 
titers which indicated a host response against the injected foreign protein and which 
warned against a possible anaphylactic reaction. Note the insidious onset of late rejection 
after cessation of globulin therapy. This was treated by increasing the maintenance dose 
of steroids. This delayed complication was seen in only two of the original 20 patients 
whose survival is shown in figure 8. (By permission of Surg. Gynec. Obstet. 126: May, 
1968.) 
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The first patient was treated in this way in June 1966. From then 
until the following December, 19 more were added to the series 
One of the patients died during the second postoperative month as 
the direct consequence of a technical surgical accident. The others 
are alive with good renal function from their original homografts 
from 15 to 21 months later for a current survival of 95 %. An addi-
tional 45 patients have since been treated with comparable results. 
The ALG-treated recipients received kidneys from blood relatives. 
The results obtained in the first ALG series are shown graphically in 
figure 8 and compared with those obtained in previous intrafamilial 
transplantations in our institutions. For the latter purpose the con-
sanguineous transplantations in the original Series I were divided into 
two consecutive groups, now termed Series 1A and 1B; this was done 
to evaluate the effect of increased experience upon results. The intra-
familial homo transplantations described in the above section on 
histocompatibility typing were Series 2. In each of the consecutive 
earlier series the mortality in comparable follow-up intervals had been 
from 28 to 31 %. 
The explanation for the improved results in the ALG-treated 
patients was not better histocompatibility matching as has been 
documented elsewhere in detail [72, 81]. The apparent reason is 
shown in figure 9. During the time when the sequential earlier series 
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(solid). Shown are the retrospective control series (Groups lA, IB and 2) and the ALG 
series (Group 3). Inclusion in the analysis was contingent upon survival for 294 days, 
a condition which was met with the highest regularity in the ALG patients. 
were being accumulated, there had been a progressive tendency to 
use smaller doses of azathioprine both during the first four and the 
subsequent six postoperative months. This trend continued into the 
ALG series. 
However, as the average doses of azathioprine were cut, there had 
been compensatory increases in the quantities of prednisone which 
were necessary to maintain a somewhat poorer quality renal function 
(figure 9, middle and right). The result of the slowly evolving adjust-
ments in policy was a change in the causes of death as described from 
our institutions by HILL et al. [22]. The early mortality from bone 
marrow depression and pyogenic infections was virtually eliminated. 
This was replaced by a delayed mortality which was usually due to un-
treatable infections caused by unusual opportunistic microorganisms. 
The situation was drastically reversed in the ALG-treated patients 
in that the quantities of average daily prednisone could be sharply 
lowered during the first four postoperative months when ALG was 
being given. Furthermore, the steroid doses remained at acceptably 
low levels in the next six months after the ALG had been stopped. 
The ability to reduce the stringency of therapy with both azathioprine 
and prednisone was not paid for with a loss of renal function (fig. 9, 
right) since all measures of renal function in the ALG-treated patients 
were at least as adequate as in the earlier series. 
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The extremely favorable showing of the ALG as compared to 
earlier series was in spite of a sharp bias introduced by the method of 
analysis. Inclusion of any case in the studies shown in figure 9 was 
contingent upon survival for ten months. A substantial fraction of 
the worst patients in each of the retrospective series were thereby 
eliminated by their death. Inasmuch as only one of the 20 patients in 
the ALG group was similarly excluded, the latter series was much 
less selective. 
This experience with ALG suggests that its use as an immuno-
suppressive agent has improved the management of patients after 
transplantation. However, there have been a number of side effects, 
recently summarized by KASHIWAGI et al. [32]. Sensitization to the 
repeatedly injected horse protein has in time led to a number of skin 
rashes. Fever and pain at the injection sites were invariable. In nearly 
20 % of cases an anaphylactic reaction occurred at some time during 
the course of therapy. The most serious of these adverse effects 
usually were observed when titers of host precipitating antibodies 
had reached high levels. Interestingly, the easily detectable antibodies 
were directed against the alpha and beta: globulins which were present 
in small quantities in the ALG; only rarely were precipitins found 
against the equine gamma G globulin which is thought to be the 
biologically active part of ALG. Consequently, there is reason to hope 
that the pure gamma G globulin (IgG) which is now being produced 
in bulk as discussed earlier will eliminate some of the undesirable 
features of ALG. 
One of the most disquieting possibilities with the clinical use of 
heterologous ALG was that the renal homografts would become the 
site of serum sickness or direct nephrotoxic Masugi-like nephritis. 
This fear has been largely dispelled. The first 8 patients treated with 
ALG received homograft biopsies at the end of their 4-month course 
of therapy. The specimens were studied with immunofluorescence and 
ferritin-labeled antibody techniques [81]. There was no trace of horse 
protein. Since then four more kidneys have been studied. In only one 
was there detectable horse protein, and in that patient there has been 
no clinical or biochemical evidence of serum sickness nephritis. 
Thymectomy in Clinical Transplantation 
In adult mice, rats, and hamsters the performance of complete thymec-
tomv causes a slowly developing loss in immunologic reactivity in 
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otherwise unaltered animals [49, 50, 68, 86]. The process can be 
accelerated in skin homotransplantation experiments if immunosup-
pressive therapy is given either with total body irradiation [9, 49] or 
with antilymphocyte serum [29, 51]. 
Shortly after the appearance of the first of the above reports, 
eight patients were subjected to thymectomy at our institutions 14 to 
85 days before renal homotransplantation. Four of the patients died 
within a few weeks or months after receipt of their homografts. The 
other four are still alive more than five years later, all with excellent 
renal function. As has been previously stressed [78, 79], the role of 
thymectomy in the attainment of long term graft function in these 
cases was essentially unanalyzable. 
In order to clarify this issue, a formal study of the effect of thymec-
tomy was carried out in 46 more patients who were treated with renal 
homotransplantation from October 1964 until June 1966. All kidneys 
were provided by living donors of whom 37 % were unrelated. 
A decision for or against thymectomy was made on the basis of 
random selection from appropriately marked cards. The spectrum of 
histocompatibility typing as well as a number of other variables 
proved to be almost identical in the 22 control cases as compared 
to the 24 cases in which transthoracic thymectomy was carried out 
before transplantation. 
The duration of follow-up for these cases is now from 21 to 41 
months. The results were assessed on the basis of early and late 
mortality (fig. 10), the dosages of immunosuppressive drugs necessary 
to retain stable homograft function, and the quality of both early and 
late renal function. There were no statistically significant differences 
between the thymectomized and non-thymectomized groups in any 
of these measures. In all 46 cases samples of the transplanted kidneys 
are now available for examination either as a result of autopsy or late 
biopsy. The histopathologic examination has not yet revealed clear 
differences between the test and control series of kidneys, although 
the specimens are currently being reviewed for the possibility that 
there may be subtle differentiating features. 
At the moment, however, it can be concluded that an important 
benefit did not derive from thymectomy. This does not, of course, 
prove that the thymus has no immunologic function in adult man. 
At the least, however, it does indicate that other factors are so much 
more important in determining survival and homograft function that 
the loss of the thymus resulted in no detectable changes under the 
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Fig. 10. Life survival curves of 24 patients who received pretransplantation thymectomy 
and 22 patients who did not. The minimum followup is 21 and 28 months in the related 
and non-related groups respectively. The crosses indicate that one additional patient in 
each of the three groups subsequently died after the period shown. Note that the thymec-
tomy did not influence either the short- or long term survival. 
experimental conditions which existed from 1964 to 1966. Conceivably 
future improvements in management might permit unmasking of a 
presently unrecognizable subtle effect of thymectomy but, at present, 
there seems to be no justification for the continued use of the proce-
dure in clinical organ transplantation. 
Post-Transplantation Neoplasia 
In 1966, SCH\VARTZ et al. [66] described the development of malignant 
lymphomas after homotransplantation of lymphoid tissues in mice; 
the genesis of the neoplasm was thought to be related in some way 
to a subclinical graft-versus-host reaction. They stated: "The practical 
importance of these findings to those attempting the transplantation 
of allogenic bone marrow or lymphoid tissue remains to be deter-
mined. Nevertheless, it might be appropriate to consider them along 
with other possible hazards of tissue transplantation". 
Two of our recipients of renal homo grafts have developed and 
died of reticulum cell or lymphosarcoma, and it is known that Dr. 
C. HITCHCOCK [24] of Minneapolis has had a similar patient. The close 
resemblance of the human tumors to some of those induced by 
SCHWARTZ et al. in animals could conceivably be more than a coin-
cidence. If so, these may be the first clinical examples of a new and 
serious complication of transplantation. 
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The three cases had in common the facts that consanguineous 
kidneys were transplanted (brother, father, and mother), that the 
donors have not subsequently had evidence of neoplasia with follow-
ups of one to four years, and that the recipients were young (14 to 
27 years) and all received immunosuppression with azathioprine and 
prednisone. One of the patients had thymectomy before transplanta-
tion. Another received heterologous antilymphocyte globulin (ALG) 
before and afterwards. The third received neither of these adjuvant 
measures. The malignancies led to death 6 months, 14 months and 
2 Yz years after homotransplantation. It was not possible to determine 
where the tumors originated but the major sites of involvement were 
the brain in one patient, the liver in another, and the liver and lung 
in the third. 
In connection with Schwartz's hypothesis of a graft-versus-host 
etiology of analogous neoplasms in mice, it is of interest that a small 
amount of lymphoid tissue is invariably transferred with renal homo-
grafts. This was well demonstrated by the studies of WILSON and 
KIRKPA'fRICK [99] who showed that delayed hypersensitivity reactions 
present in donors were always transferred to previously negative 
recipients and there persisted for months. 
Hyperacute Rejection 
As mentioned earlier, it was soon learned that renal homografts had 
a significant risk of being immediately destroyed if the donors and 
recipients had different ABO red cell groups in the combinations 
shown in table 1. A rational explanation was available since the iso-
agglutinogens which allow red cells to be typed are also found in 
other tissues including the kidney [26, 85]. Thus if the kidney of an 
Table 1. Direction of acceptable mismatched tissue transfer! 
o to non-O 
RH-to RH + 
RH + to RH-
A to non-A 
B to non-B 
AB to non-AB 
lOis universal donor; AB is universal recipient. 
Safe 
Safe 
Relatively Safe 
Dangerous 
Dangerous 
Dangerous 
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A or B donor were placed in a patient of 0 blood type, the naturally 
occurring anti-A and anti-B isoagglutinins respectively in the serum 
of the recipient could be expected to bind with the renal red cell 
antigens; serologic studies by WILSON and KIRKPATRICK provided 
strong evidence that this actually occurred [99]. 
In cases where the homografts were immediately lost, the sequence 
was typical. After opening the renal vessels, the kidney cortex was 
not well vascularized although the medulla, pelvis, and ureter ap-
parently had a good blood supply. These soft and cyanotic kidneys 
which were removed within a few hours had histologic evidence of 
widespread small vessel thrombosis [69]. A frank red cell group mis-
match did not always lead to this kind of accident. One of our patients 
has normal renal function more than five years after transplantation 
under such circumstances. 
Recently, there have been reports of similar catastrophes where 
there was conformity of red cell types. The first case was described 
briefly by TERASAKI [87] and others were added by KISSMEYER-
NIELSEN [37], WILLIAMS [96, 97], and TERASAKI [89]. In the serum 
of many but not all of these patients preformed antibodies were 
present preoperatively which reacted against donor white cells. This 
fact has resulted in speculation that such antibodies were directly 
responsible for the homograft destruction by virtue of a high grade 
nephrotoxicity [37, 96]. Our own studies on "hyperacute rejection" 
in the absence of red cell mismatching, carried out in collaboration 
with R. LERNER and F. DIXON of La Jolla, California, have led us to 
a different conclusion as recently reported in detail [73]. In five kidneys 
which sustained "rejection on the operating table", there was un-
equivocal evidence of a generalized Shwartzman reaction. With im-
munofluorescence techniques, LERNER and DIXON found massive 
fibrin deposition in the small vessels and glomerular capillaries and 
consequent cortical necrosis exactly as in an experimentally induced 
Shwartzman reaction. There was little or no immunoglobulin deposi-
tion detectable by immunofluorescence [73] although eluates of some 
of the kidneys were later shown by Dr. F. MILGROM of Buffalo, New 
York, to contain leukoagglutinins. In three of the five instances, the 
kidney donors had been shown by TERASAKI to have a good histo-
compatibility match with the recipients. 
The generalized Shwartzman reaction was first described in 1934, 
but its significance as summarized by LEE and STETSON [42] and HJORT 
and RAPAPORT [25], was not understood until the last decade. Clas-
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sically, it is produced in rabbits by two injections of endotoxin spaced 
at 24 h intervals. A generalized coagulapathy is produced. If the 
animal reticuloendothelial system (RES) can clear the breakdown 
products of fibrinogen rapidly enough, the kidney is spared from 
injury. If not, it becomes a primary target because the specific qualities 
of the renal microcirculation make it an exceptionally good fibrin 
filter. The result is cortical devascularization and necrosis. 
A number of factors besides endotoxin can condition or precipitate 
a Shwartzman reaction, including antigen-antibody reactions; injec-
tion of thorotrast, carbon black, or steroids; or administration of an 
oxidized lipid diet. Their effects are incompletely understood but 
presumably they could be influential by either reinforcing the coagula-
pathy and/or by reducing the efficiency of RES function, or by sup-
pressing counter-regulatory fibrinolysis. 
In several ways, the recipient of a renal homograft could be 
expected to be a good candidate for a Shwartzman reaction. Before 
operation, he undergoes multiple hemodialyses with attendant risks 
from accidental exposure to endotoxin in the extracorporeal circuit 
[34], from an additional loss of RES efficiency caused by increased 
blood hemolysis [5] and other factors of extracorporeal circulation 
[84], and from the rapid changes in coagulation which occur with this 
procedure [94]. With multiple blood transfusions, there is an increased 
chance that he will develop antibodies against antigens in infused 
white blood cells or red cell subgroups, and that these will later react 
with the same antigens in the homograft. The operation itself intro-
duces the latter possibility as well as that of a full spectrum of other 
potential triggering antigen-antibody reactions either within or out-
side the freshly transplanted kidney. Intra- and postoperatively 
steroids, which can potentiate a Shwartzman reaction by causing 
RES paralysis [92], are commonly used. 
Recognition that many, and possibly even most, "rejections on the 
operating table" are due to Shwartzman reactions has practical im-
plications. Prophylactic measures can be taken. Greater attention can 
be paid to the details of hemodialysis including asepsis and hemolysis 
rates. The value of white cell free blood for transfusion is obvious. 
Immunologic tests to detect presensitization are available; when such 
an examination is positive in a recipient, the hazards are predictably 
increased [89, 97]. Under these circumstances, it may be advisable to 
use total body heparinization at the time of transplantation. This 
was done in two of our patients whose previously placed kidney 
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transplants had been immediately destroyed; the final homografts 
functioned well [73]. Once a Shwartzman reaction has started, a 
combination of heparin and fibrinolysin therapy might be worth 
a trial. 
It is probable that most and perhaps even all Shwartzman reactions 
are ultimately triggered by antigen-antibody unions of one sort or 
other at the time of transplantation. If these are intrarenal, they may 
be inherently benign or even undetectable with immunofluorescence 
studies as in our cases and of significance only by virtue of the de-
vastating secondary effects which they can initiate depending upon 
a variety of other conditions. If, as is now thought, the site of the 
immunologic reaction is not critical to the chain of events, it is 
conceivable that the Shwartzman reaction may lead to destruction 
of the kidneys after transplantation of other organs. 
Cadaveric Transplantation 
A cadaveric renal homograft was first transplanted in Denver in April 
1963. This recipient, as well as the next two, died within 39 days. 
The kidneys either functioned poorly or not at all. No more cadaveric 
transplantations were performed for more than two years. 
The program was reopened in November 1965. From then until 
July 1967, 12 patients received as their primary homograft the kidney 
of a blood group compatible cadaver. In each case, a minimum follow-
up of eight months is available. 
Six of these 12 recipients died after 13, 10, 8, 3 Yz, 3 Yz, and 3 
months. The other six are still alive after 27, 24, 15, 10, 9, and 8 
months. However, one of the latter patients required transplant 
nephrectomy and regrafting one year after receipt of his first kidney; 
another lost his homograft after a year and is presently anephric 
15 months post-transplantation. 
The last six patients in this series received ALG therapy for the 
first several postoperative months. In all cases, the donor-recipient 
histocompatibility matches as determined by TERASAKI were poor. 
Two of the recipients who had received their kidneys from a common 
cadaveric donor, died within a one day interval more than three 
months postoperatively. Death was caused by pulmonary emboli. 
The homografts had little or no evidence of rejection. 
The other four patients including one with preformed lympho-
cytotoxic antibodies had good or excellent renal function during the 
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four month period of ALG therapy. After its discontinuance, all have 
had evidence of slow but progressive rejection. 
Other groups with much more extensive experience in cadaveric 
transplantation have repeatedly expressed optimism about the bright 
future of this approach [6, 27, 35, 36, 45]. It is a point of view with 
which few would disagree especially since the prospects of transplant-
ing livers, lungs, and hearts will depend upon the use of cadaveric 
organs. Nevertheless, it is worth emphasizing that the costs in 
mortality, morbidity, and rehospitalization have been high in all 
centers. Furthermore, survival exceeding four years with continuous 
function of non-related renal homografts is rare. To our knowledge 
there are only four patients whose courses have been this long; one 
of Dr. W. GOODWIN who was treated at UCLA in June 1963, another 
who has been followed by Dr. D. HUME of Richmond since August 
of that year, and two more who were in our Series 1. 
Ribonucleic Acid (RNA) Perfusion 
Many of the problems of organ transplantation could be minimized 
if it were possible to mitigate graft rejection by modifying the trans-
planted tissue rather than the host immunologic response. Efforts to 
achieve this objective have been unsuccessful with occasional possible 
exceptions [2,21,30] of which the most intriguing was described by 
JOLLEY, HINSHAW, and PETERSON [30]. They reported that rabbit skin 
grafts which were first immersed in homologous ribonucleic acid 
(RNA) and then transplanted to recipient animals which were given 
intravenous RNA had a survival four times longer than controls. 
The role of the preliminary soaking was not analyzable in these 
experiments, but the authors also reported that human skin homo-
grafts subjected only to RNA soaking had unusually protracted 
viability when placed upon patients with burns [31]. 
In our laboratories similar attempts to "pre-treat" whole organ 
homografts have been made in dogs by perfusing kidneys for about 
30 min with RNA prepared by phenol extraction from the spleens 
of the prospective recipients (autologous RNA) or other dogs (homo-
logous RNA). After transplantation to unmodified recipients, about 
one fourth of these life sustaining organs had prolonged homograft 
viability [14]. Maximum survival of recipients, which were subjected 
to simultaneous removal of their own kidneys, was 123 days. The 
mean survival in a group of 40 recipients was more than 20 days as 
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opposed to approximately 10 days in 30 control animals. Further-
more, there were seven homo grafts of the 40 which had no histologic 
evidence of rejection whereas all the control homografts had the 
typical findings of unmodified rejection. The protection afforded by 
recipient specific RNA was not significantly different from that ob-
tained with homologous RNA. 
The foregoing effect was not increased by the addition of a sup-
posed RNase inhibitor, DEAE-dextran, but it was abolished by the 
addition of commercial RNase. The treatment of renal autografts 
with homologous RNA did not result in their rejection. The latter 
finding, and the fact that the results after homotransplantation were 
equivalent with either homologous or autologous RNA, suggest that 
the homograft protection was not due to RNA-induced changes in 
the genetic characteristics of the cells. 
The significance of the foregoing findings is quite unclear since 
a logical explanation for the surprising results is not available, and 
because the degree of homograft protection was relatively limited. 
It will be of interest in laboratory experiments to determine whether 
or not such graft conditioning can be advantageously combined with 
effective host immunosuppression. 
~iver ~ransjg!antation 
Until last year, the kidney was the only vital organ which had been 
transplanted with resulting significant prolongation of life. There had 
been nine attempts at orthotopic liver transplantation; seven in Denver 
[70, 80], and one each in Boston [53] and Paris [10]. Two of these 
patients had succumbed within a few hours after operation, and none 
had lived for longer than 23 days. 
This dismal picture has changed within the last nine months, 
inasmuch as six consecutive children treated with orthotopic liver 
transplantation from July 1967 to February 1968 all passed through 
this previously lethal operative and postoperative period. Two of the 
patients are still alive after 8 and 1 Y2 months respectively; the others 
died after 2, 3 Y2, 4 Y2, and 6 Y2 months. The better results were the 
product of several improvements in care as reported elsewhere [71J. 
First, a very efficient technique of preservation had been developed 
in dogs which permitted livers to be stored for 8 to 24 hours and then 
successfully transplanted as orthotopic homografts [3]. The method 
which combined hypothermia, low flow perfusion with diluted blood, 
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and hyperbaric oxygenation, was used in the clinical cases for several 
hours after death of the donors and until the recipients could be 
prepared. Good immediate hepatic function was obtained in each 
case (fig. 11). 
In each of these cases, the compatibility of the donor and recipient 
white cell antigens was studied by TERASAKI in advance of operation. 
A good match with compatibility in all six currently recognized 
components of the recently defined HLA system [90] was present 
only in one case. In three, there were breeches in one major antigen 
group and in the other two there were mismatches in two of the 
six groups. 
A conservative attitude toward immunosuppression was taken 
during the early postoperative period, particularly in the dosages of 
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Fig. 11. Course of a 1 y, year old girl who was treated with orthotopic hepatic homo-
transplantation. The indication for the operation was a hepatoma. Note the essentially 
stable liver function except at the times of septic liver infarctions which were treated 
with debridement. The septicemia, indicated by encircled crosses, was with various gram 
negative rods or candida albicans. The thoractomy was for an unexpanded right upper 
lobe. The laparotomy was for excision of a tumor recurrence. 
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azathioprine (fig. 11). High initial doses of prednisone were given 
but rapidly reduced. Finally, heterologous antilymphocyte globulin 
(ALG) was administered in a course (fig. 11) similar to that described 
earlier after renal homotransplantation. 
The six recipients were all infants. The indication for operation 
was a hepatoma in the first patient and extrahepatic biliary atresia 
in the other five. In all but one case, the early convalescence was 
remarkably rapid. Pre-existing jaundice was quickly cleared. Eating 
was begun on the second to fourth postoperative days. 
A specific life threatening complication was encountered in five 
of the six patients. From two days to two months postoperatively, 
septicemia with gram negative microorganisms interrupted recovery. 
This was accompanied by high increases in SGOT and SGPT (fig. 11) 
and eventually septic infarctions within the liver were found. Liver 
scans showed filling defects which involved the right lobe (fig. 12). 
In one case, the development of hepatic sepsis was not surprising 
inasmuch as a serious technical accident could be implicated. The 
homograft had been found to have a double arterial supply and the 
two vessels were anastomosed to the terminal right and left branches 
of the recipient hepatic artery. The artery to the right lobe thrombosed 
on the second postoperative day eventually necessitating a partial 
right lobectomy. In the four other children the complication occurred 
after a benign early postoperative course. Two of the latter patients 
who died from this complication were also found at autopsy to have 
thrombosed right hepatic arteries. 
The unusual susceptibility of the transplanted liver to invasion by 
enteric organisms is not surprising in view of its perfusion by splanch-
nic venous blood, as well as the necessity for connecting its biliary 
drainage system to the intestinal tract. However, the precise patho-
genetic events of the septic liver infarctions can only be speculated 
upon in the individual cases. In a recent analysis of the problem in 
dogs [4], any factor which caused liver necrosis, including the injury 
of rejection, was shown to predispose to liver abscess formation. It 
is possible that, in at least some of the clinical cases, the intensity of 
immunosuppression was inadequate, that the infarctions were a mani-
festation of the reduced blood flow known to accompany rejection 
[15], and that the bacterial invasion was a secondary event. In at least 
three of the patients, however, rejection did not seem to be severe 
when the right hepatic artery thrombosed. In these cases, the differ-
entiation of mechanical from immunologic factors was not possible. 
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Fig. 12. Liver scan performed one month after hepatic homotransplantation in the 1 12 
year old patient whose course is depicted in figure 11. Anteroposterior (upper) as well 
as lateral views (lower) show large defect (arrows). Exploration revealed a septic infarct 
in the homograft. 
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Once established in the clinical cases, the infected liver infarcts 
required aggressive therapy. Debridement and drainage were carried 
out through lateral incisions in the right 10th intercostal space, taking 
care to enter neither the chest nor abdomen. These local measures 
plus therapy with properly chosen antibiotics tided three patients 
over the crisis but two of these eventually died. Two other recipients 
died within a few days after the onset of the complication. 
An alternative to orthotopic liver transplantation has also been 
given a clinical trial, namely transplantation of an auxiliary organ. 
Only five cases have been reported [1,8, 16] but it is known that many 
more have been attempted. The longest survival after auxiliary liver 
transplantation has been 34 days [16]. Analyses of the special physio-
logic and technical difficulties with this approach have been published 
[46], suggesting that it may be a less desirable procedure than the 
orthotopic operation. 
Summary 
Several separate issues in organ transplantation have been reviewed based upon our own 
experience with renal and liver transplantation. The topics surveyed include a reconsidera-
tion of rejection reversal and host-graft adaptation, projections of survival after renal 
homotransplantation in the past and today, the role of histocompatibility typing, im-
provements in immunosuppression, an evaluation of thymectomy, the development of 
neoplasms in post-transplantation patients, and the contribution of the Shwartzman 
reaction to "hyperacute rejection". In addition, a specific problem of hepatic sepsis 
after liver transplantation has been described. 
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